Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.

Wagner C, Visvanathan S, Braun J, van der Heijde D, Deodhar A, Hsu B, Mack M, Elashoff M, Inman RD.

Ann Rheum Dis. 2012 May;71(5):674-80. doi: 10.1136/ard.2010.148890. Epub 2011 Oct 28.

2.

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.

Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B.

Ann Rheum Dis. 2012 May;71(5):661-7. doi: 10.1136/ard.2011.154799. Epub 2011 Oct 19.

3.

Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.

Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van der Heijde D.

Arthritis Care Res (Hoboken). 2010 Sep;62(9):1266-71. doi: 10.1002/acr.20233.

4.

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

Inman RD, Davis JC Jr, Heijde Dv, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J.

Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969.

5.

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study.

Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, Baratelle A, Xu S, Xu W, Hsu B.

Ann Rheum Dis. 2012 Jun;71(6):878-84. doi: 10.1136/annrheumdis-2011-200308. Epub 2011 Nov 29. Erratum in: Ann Rheum Dis. 2013 May;72(5):788.

6.

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.

Inman RD, Baraliakos X, Hermann KA, Braun J, Deodhar A, van der Heijde D, Xu S, Hsu B.

Arthritis Res Ther. 2016 Dec 28;18(1):304. doi: 10.1186/s13075-016-1200-1.

7.

Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Oldfield V, Plosker GL.

BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005. Review.

PMID:
19489653
8.

Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study.

van der Heijde D, Deodhar A, Inman RD, Braun J, Hsu B, Mack M.

Arthritis Care Res (Hoboken). 2012 Dec;64(12):1919-22. doi: 10.1002/acr.21771.

9.

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.

Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B.

Ann Rheum Dis. 2015 Apr;74(4):757-61. doi: 10.1136/annrheumdis-2014-205862. Epub 2014 Nov 11.

10.

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.

Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC.

Rheumatology (Oxford). 2014 Sep;53(9):1654-63. doi: 10.1093/rheumatology/keu132. Epub 2014 Apr 11.

PMID:
24729398
11.

The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.

van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C; GO-RAISE investigators..

J Rheumatol. 2014 Jun;41(6):1095-103. doi: 10.3899/jrheum.131003. Epub 2014 Apr 15.

PMID:
24737912
12.

Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).

van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B.

Rheumatology (Oxford). 2013 Feb;52(2):321-5. doi: 10.1093/rheumatology/kes251. Epub 2012 Sep 28.

PMID:
23024015
13.

A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.

Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, Berd Y, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng HH.

Arthritis Rheumatol. 2015 Oct;67(10):2702-12. doi: 10.1002/art.39257.

14.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

15.

TNF-alpha inhibitors for ankylosing spondylitis.

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2. Review.

PMID:
25887212
16.

Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.

Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C.

Arthritis Res Ther. 2010;12(6):R211. doi: 10.1186/ar3188. Epub 2010 Nov 17.

17.

Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis.

Venetsanopoulou AI, Voulgari PV, Alamanos Y, Papadopoulos CG, Markatseli TE, Drosos AA.

Rheumatol Int. 2007 Aug;27(10):935-9. Epub 2007 Mar 15.

PMID:
17357804
18.

Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.

Davis JC Jr, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.

J Rheumatol. 2005 Sep;32(9):1751-4.

PMID:
16142873
19.

Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial.

Mok CC, Li OC, Chan KL, Ho LY, Hui PK.

Scand J Rheumatol. 2015;44(6):480-6. doi: 10.3109/03009742.2015.1038300. Epub 2015 Aug 14.

PMID:
26271141
20.

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.

Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL.

Ann Rheum Dis. 2012 May;71(5):700-6. doi: 10.1136/annrheumdis-2011-200358. Epub 2011 Nov 29.

Supplemental Content

Support Center